JBIO vs. CAPR
JBIO (Jade Biosciences, Inc) and CAPR (Capricor Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, JBIO returned 67.87%/yr vs 35.55%/yr for CAPR. At a 0.18 correlation, their price movements are largely independent.
Performance
JBIO vs. CAPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JBIO achieves a 35.77% return, which is significantly higher than CAPR's -25.47% return.
JBIO
- 1D
- -6.81%
- 1M
- 36.57%
- 6M
- 54.84%
- YTD
- 35.77%
- 1Y
- 113.34%
- 3Y*
- 123.63%
- 5Y*
- 67.87%
- 10Y*
- —
CAPR
- 1D
- -4.40%
- 1M
- -16.63%
- 6M
- -9.77%
- YTD
- -25.47%
- 1Y
- 181.54%
- 3Y*
- 68.83%
- 5Y*
- 35.55%
- 10Y*
- -6.11%
JBIO vs. CAPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
JBIO Jade Biosciences, Inc | 35.77% | 5,473.10% | -88.29% | -22.76% | 148.52% | -57.89% |
CAPR Capricor Therapeutics, Inc. | -25.47% | 109.13% | 182.21% | 26.68% | 31.74% | -44.72% |
Correlation
The correlation between JBIO and CAPR is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 2021 | 0.18 |
Fundamentals
JBIO:
$683.51M
CAPR:
$983.37M
JBIO:
-$2.65
CAPR:
-$2.26
JBIO:
4.08
CAPR:
0.00
JBIO:
$0.00
CAPR:
$0.00
JBIO:
-$9.00K
CAPR:
-$42.41M
JBIO:
-$133.57M
CAPR:
-$117.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JBIO vs. CAPR — Risk / Return Rank
JBIO
CAPR
JBIO vs. CAPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Jade Biosciences, Inc (JBIO) and Capricor Therapeutics, Inc. (CAPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JBIO | CAPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.05 | ||
| Sortino ratioReturn per unit of downside risk | -2.90 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.63 | -0.39 |
| Calmar ratioReturn relative to maximum drawdown | 2.26 | 1.81 | +0.45 |
| Martin ratioReturn relative to average drawdown | 5.83 | 4.19 | +1.64 |
Loading charts...
Drawdowns
JBIO vs. CAPR - Drawdown Comparison
The maximum JBIO drawdown since its inception was -95.41%, roughly equal to the maximum CAPR drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for JBIO and CAPR.
Loading charts...
Drawdown Indicators
| JBIO | CAPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.41% | -99.97% | +4.56% |
Max Drawdown (1Y)Largest decline over 1 year | -44.21% | -49.28% | +5.07% |
Max Drawdown (3Y)Largest decline over 3 years | -95.41% | -79.08% | -16.33% |
Max Drawdown (5Y)Largest decline over 5 years | -95.41% | -79.08% | -16.33% |
Max Drawdown (10Y)Largest decline over 10 years | — | -97.80% | — |
Current DrawdownCurrent decline from peak | -21.97% | -99.34% | +77.37% |
Average DrawdownAverage peak-to-trough decline | -44.86% | -90.27% | +45.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.80% | 29.58% | -10.78% |
Volatility
JBIO vs. CAPR - Volatility Comparison
Jade Biosciences, Inc (JBIO) has a higher volatility of 24.05% compared to Capricor Therapeutics, Inc. (CAPR) at 21.76%. This indicates that JBIO's price experiences larger fluctuations and is considered to be riskier than CAPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JBIO | CAPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.05% | 21.76% | +2.29% |
Volatility (6M)Calculated over the trailing 6-month period | 54.92% | 50.00% | +4.92% |
Volatility (1Y)Calculated over the trailing 1-year period | 77.79% | 382.18% | -304.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 1,580.66% | 190.03% | +1,390.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 1,576.34% | 179.66% | +1,396.68% |
Dividends
JBIO vs. CAPR - Dividend Comparison
Neither JBIO nor CAPR has paid dividends to shareholders.
| Position | TTM | 2025 |
|---|---|---|
CAPR Capricor Therapeutics, Inc. | 0.00% | 0.00% |
JBIO Jade Biosciences, Inc | 0.00% | 15.55% |
Financials
JBIO vs. CAPR - Financials Comparison
This section allows you to compare key financial metrics between Jade Biosciences, Inc and Capricor Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
JBIO and CAPR have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
JBIO has higher volatility (24.05%) compared to CAPR (21.76%). In terms of maximum drawdown, JBIO dropped -95.41% vs CAPR's -99.97%.
JBIO currently has the higher Sharpe Ratio (1.28 vs 0.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JBIO and CAPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer